— Know what they know.
Not Investment Advice

NBSE NASDAQ

NeuBase Therapeutics, Inc.
1W: +0.0% 1M: -14.5% 3M: -59.0% 1Y: -90.5% 3Y: -99.6% 5Y: -99.3%
$0.38
Last traded 2024-05-24 — delisted
NASDAQ · Healthcare · Biotechnology · $1.4M mcap · 3M float · 3.83% daily turnover

Balance Sheet Trends

Total Assets
$33M -49.0% ▼
5Y CAGR: +3.2%
Total Liabilities
$10M -5.9% ▼
5Y CAGR: +13.3%
Shareholders Equity
$23M -57.1% ▼
5Y CAGR: +0.3%
Cash & Investments
$23M -56.2% ▼
5Y CAGR: +12.6%
Total Debt
$6M -8.4% ▼
5Y CAGR: +124.0%
Net Debt
-$17M +63.0% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2018FY2019FY2020FY2021FY2022
— Assets —
Cash$4M$10M$32M$53M$23M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$4M$10M$32M$53M$23M
Net Receivables$0$0$0$0$128K
Inventory$0$0$0$0-$128K
Other Current Assets$248K$266K$295K$2M$1M
Total Current Assets$4M$11M$33M$55M$25M
Property, Plant & Equip.$16K$431K$1M$8M$8M
Goodwill & Intangibles$8M$146K$0$0$0
Long-Term Investments$0$586K$324K$416K$0
Other Non-Current Assets$0$339K$145K$414K$273K
Total Non-Current Assets$8M$2M$2M$9M$8M
Total Assets$12M$13M$34M$64M$33M
— Liabilities —
Accounts Payable$22K$1M$2M$2M$2M
Short-Term Debt$73K$123K$139K$639K$661K
Deferred Revenue-$22K$406K$556K$0$0
Other Current Liabilities$652K$496K$950K$2M$2M
Total Current Liabilities$725K$3M$3M$4M$4M
Long-Term Debt$250K$0$0$6M$5M
Other Non-Current Liab.-$250K$0$0-$0$0
Total Non-Current Liabilities$73K$0$2M$6M$5M
Total Liabilities$725K$3M$3M$10M$10M
— Equity —
Common Stock$6K$2K$2K$3K$3K
Retained Earnings-$121M-$27M-$44M-$69M-$103M
Accumulated OCI-$94K$0-$0$0$0
Total Stockholders Equity$11M$10M$31M$54M$23M
Total Liabilities & Equity$12M$13M$34M$64M$33M
— Key Metrics —
Total Debt$73K$123K$139K$7M$6M
Net Debt-$4M-$10M-$32M-$46M-$17M
Total Investments$0$586K$324K$416K$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms